MONDAY, April 15, 2019 -- Canagliflozin is associated with a reduced risk for renal and cardiovascular events for patients with type 2 diabetes and kidney disease, according to a study published online April 14 in the New England Journal of Medicine...
Original Article: Canagliflozin Seems Effective for Patients With T2DM, Kidney Disease